2023年11月28日，由国际知名咨询机构IMAPAC举办的“亚太地区疫苗卓越奖”颁奖典礼在新加坡滨海湾金沙国际会议中心隆重召开。博沃生物凭借在创新疫苗方面的卓越表现，被授予“2023年亚太地区最具潜力候选疫苗奖”，这也是系列奖项中的最高荣誉奖。博沃生物CEO吴克博士作为重要嘉宾受邀做大会报告，参加嘉宾圆桌讨论，并出席本届颁奖典礼。
2023年亚太地区疫苗卓越奖旨在表彰亚洲疫苗和供应链专家、组织和最新技术的杰出成就，致敬顶级疫苗行业领导者以及研发和制造领域的最新技术，激励未来的创新者。此次获评“2023年亚太地区最具潜力候选疫苗奖”，是对博沃生物疫苗行业领导者、研发技术创新性的极大肯定与鼓励。
未来，博沃生物将继续深耕疫苗领域、坚持技术创新，以最好的生物品质服务于健康事业，致力于成为全球疫苗行业的先锋。
On November 28th, 2023, the awards ceremony for Asia Pacific Vaccine Excellence Awards 2023,organized by the internationally renowned consulting firm IMAPAC, was grandly held at the Marina Bay Sands International Convention Center in Singapore. BravoVax Co., Ltd (BravoVax) was awarded the "Most Promising Vaccine Candidate in APAC" for its outstanding performance in vaccine innovations. The “Most Promising Vaccine Candidate in APAC” was also the highest honor award in the series of awards. Dr. Wu Ke, CEO of BravoVax, was invited to give a speech at the conference, participate in panel discussions and attend this awards ceremony.
The purpose of Asia Pacific Vaccine Excellence Awards (AVEA) 2023 is to recognize the outstanding achievements of vaccine & supply chain experts, organizations, and the newest technologies in Asia. The Asia Pacific Vaccine Excellence Award applauds extraordinary leaders & trendsetters of today and inspires the innovators of tomorrow. Grand winner of the “Most Promising Vaccine Candidate in APAC” this time is a great affirmation and encouragement to the leadership and R&D innovation of the BravoVax in vaccine industry.
In the future, BravoVax will continue to deeply cultivate the vaccine field, adhere to technological innovation, and serve the health industry with the best quality, committed to becoming a pioneer in the global vaccine industry.
关于博沃生物
上海博沃生物科技有限公司（简称博沃生物）2011年3月成立于上海张江高科技园区，2021年10月迁至北上海生物医药园。2012年12月设立了武汉博沃，是国家级高新技术企业、中国疫苗行业协会理事单位。2020年公司被德勤Deloitte评为“中国明日之星”，是内地唯一获奖的生物医药企业。公司具有基因编辑/构建/克隆/检测、细菌大规模培养、细胞/病毒大规模培养、生物活性物质制备（多糖、蛋白质、病毒等）、多糖与蛋白质化学结合、新型佐剂、新型制剂、新型检测等多个先进技术平台，满足各类创新型生物医药特别是疫苗开发的需要。博沃生物以满足中国和世界人民健康生活的美好愿景为己任，致力于通过重磅级创新疫苗的开发和市场化运营，成为全球疾病控制领域的主力军。
Shanghai BravoBio Co., Ltd (BravoBio) was established in Zhangjiang Hi-Tech Park in Shanghai in March 2011 and moved to MediPark in North Shanghai in October 2021. Its subsidiary company, Wuhan BravoVax Co., Ltd (BravoVax), was founded in December 2012. BravoVax is a "state level high-tech enterprise" and a council member of China Association of Vaccines (CAV). It was awarded as "China Rising Star" by Deloitte in 2020, becoming the only biopharmaceutical enterprise in Chinese mainland to win this award. The company boasts a number of advanced technology platforms, including gene editing / construction / cloning / detection, large-scale bacterial / cell / virus culture, preparation of bioactive substances (polysaccharide, protein, virus, etc.), chemical combination of polysaccharide and protein, novel adjuvant, new preparation and analytical assays, etc. to meet the needs of developing innovative biologics, especially vaccines. BravoBio has held the mission to improve the quality of people's lives, aiming for a healthier and happier future. The company is active to be a global supplier of high-quality vaccine through development and commercialization of its innovative and blockbuster vaccines, contributing to the control of global diseases.
关注博沃生物
